Anti-Influenza Effect of Nanosilver in a Mouse Model

The present study assesses copper metabolism of the host organism as a target of antiviral strategy, basing on the "virocell" concept. Silver nanoparticles (AgNPs) were used as a specific active agent because they reduce the level of holo-ceruloplasmin, the main extracellular cuproenzyme....

Full description

Saved in:
Bibliographic Details
Published inVaccines (Basel) Vol. 8; no. 4; p. 679
Main Authors Kiseleva, Irina V, Farroukh, Mohammad Al, Skomorokhova, Ekaterina A, Rekstin, Andrei R, Bazhenova, Ekaterina A, Magazenkova, Daria N, Orlov, Iurii A, Rudenko, Larisa G, Broggini, Massimo, Puchkova, Ludmila V
Format Journal Article
LanguageEnglish
Published Switzerland MDPI AG 13.11.2020
MDPI
Subjects
Online AccessGet full text

Cover

Loading…
More Information
Summary:The present study assesses copper metabolism of the host organism as a target of antiviral strategy, basing on the "virocell" concept. Silver nanoparticles (AgNPs) were used as a specific active agent because they reduce the level of holo-ceruloplasmin, the main extracellular cuproenzyme. The mouse model of influenza virus A infection was used with two doses: 1 LD and 10 LD . Three treatment regimens were used: Scheme 1-mice were pretreated 4 days before infection and then every day during infection development; Scheme 2-mice were pretreated four days before infection and on the day of virus infection; Scheme 3-virus infection and AgNP treatment started simultaneously, and mice were injected with AgNPs until the end of the experiment. The mice treated by Scheme 1 demonstrated significantly lower mortality, the protection index reached 60-70% at the end of the experiment, and mean lifespan was prolonged. In addition, the treatment of the animals with AgNPs resulted in normalization of the weight dynamics. Despite the amelioration of the infection, AgNP treatment did not influence influenza virus replication. The possibility of using nanosilver as an effective indirectly-acting antiviral drug is discussed.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
These authors contributed equally to this work as the second authors.
ISSN:2076-393X
2076-393X
DOI:10.3390/vaccines8040679